Sarepta ' s DMD gene therapy inches closer to market as FDA declines to hold advisory meeting

The FDA won’t be holding an advisory panel meeting for Sarepta Therapeutics’ SRP-9001, which is now that much closer to becoming the first gene therapy for Duchenne muscular dystrophy (DMD). | The FDA won’t be holding an advisory panel meeting for Sarepta Therapeutics’ SRP-9001, which is now that…#fda #duchenne #dmd
Source: Reuters: Health - Category: Consumer Health News Source Type: news